Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Antidepressants in epilepsy.

Górska N, Słupski J, Cubała WJ, Wiglusz MS, Gałuszko-Węgielnik M.

Neurol Neurochir Pol. 2018 Aug 11. pii: S0028-3843(18)30258-5. doi: 10.1016/j.pjnns.2018.07.005. [Epub ahead of print] Review.

PMID:
30131174
2.

Role of copper in depression. Relationship with ketamine treatment.

Słupski J, Cubała WJ, Górska N, Gałuszko-Węgielnik M, Wiglusz MS.

Med Hypotheses. 2018 Oct;119:14-17. doi: 10.1016/j.mehy.2018.07.012. Epub 2018 Jul 17.

PMID:
30122482
3.

Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment.

Włodarczyk A, Wiglusz MS, Cubała WJ.

Med Hypotheses. 2018 Sep;118:74-77. doi: 10.1016/j.mehy.2018.06.022. Epub 2018 Jun 20.

PMID:
30037619
4.

What really is a 'gold standard' in depression recognition among patients with epilepsy?

Cubała WJ, Włodarczyk A, Wiglusz MS, Szarmach J.

Epilepsy Behav. 2018 Jul 19. pii: S1525-5050(18)30478-5. doi: 10.1016/j.yebeh.2018.06.050. [Epub ahead of print] No abstract available.

PMID:
30033156
5.

Validation of the Polish version of the Hospital Anxiety and Depression Scale for anxiety disorders in patients with epilepsy.

Wiglusz MS, Landowski J, Cubała WJ.

Epilepsy Behav. 2018 Jul;84:162-165. doi: 10.1016/j.yebeh.2018.04.010. Epub 2018 May 26.

PMID:
29803946
6.

Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature.

Springer J, Cubała WJ.

J Psychoactive Drugs. 2018 Jul-Aug;50(3):275-280. doi: 10.1080/02791072.2018.1438687. Epub 2018 Mar 1.

PMID:
29494783
7.

Therapeutic drug monitoring of atypical antipsychotics.

Urban AE, Cubała WJ.

Psychiatr Pol. 2017 Dec 30;51(6):1059-1077. doi: 10.12740/PP/65307. Epub 2017 Dec 30. Review. English, Polish.

8.

Letter to Editor regarding "Characterizing and predicting rates of delirium across general hospital settings".

Wilkowska A, Wojciechowski M, Cubała WJ.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:80-81. doi: 10.1016/j.genhosppsych.2017.09.010. Epub 2017 Dec 13. No abstract available.

PMID:
29269106
9.

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S.

Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15.

PMID:
29241357
10.

Prevalence of anxiety disorders in epilepsy.

Wiglusz MS, Landowski J, Cubała WJ.

Epilepsy Behav. 2018 Feb;79:1-3. doi: 10.1016/j.yebeh.2017.11.025. Epub 2017 Dec 8.

PMID:
29223931
11.

Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy.

Wiglusz MS, Landowski J, Michalak L, Cubała WJ.

Epilepsy Behav. 2017 Dec;77:58-61. doi: 10.1016/j.yebeh.2017.09.023. Epub 2017 Nov 5.

PMID:
29111504
12.

The Role of Hormones and Inflammatory Markers in Cognitive Functioning of Schizophrenic Patients.

Krysta K, Krzystanek M, Cubała WJ, Wiglusz MS, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Czarnowska-Cubała M, Szarmach J, Włodarczyk A, Janas-Kozik M.

Psychiatr Danub. 2017 Sep;29(Suppl 3):664-666.

PMID:
28953849
13.

Telepsychiatry and Virtual Reality an the Teatment of Patients with Intellectual and Developmental Disabilities.

Krysta K, Krzystanek M, Cubała WJ, Wiglusz MS, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Czarnowska-Cubała M, Szarmach J, Włodarczyk A, Janas-Kozik M.

Psychiatr Danub. 2017 Sep;29(Suppl 3):656-659.

PMID:
28953847
14.

Lithium therapeutic dose monitoring in human saliva.

Gałuszko-Węgielnik M, Jakuszkowiak-Wojten K, Wiglusz MS, Szarmach J, Włodarczyk A, Herstowska M, Cubała WJ.

Psychiatr Danub. 2017 Sep;29(Suppl 3):361-364.

PMID:
28953792
15.

Neurosyphilis - the white matter disintegration? - two case reports.

Czarnowska-Cubała M, Włodarczyk A, Szarmach J, Gwoździewicz K, Pieńkowska J, Wiglusz MS, Cubała WJ, Krysta K.

Psychiatr Danub. 2017 Sep;29(Suppl 3):357-360.

PMID:
28953791
16.

Decision-making in panic disorder. Preliminary report.

Jakuszkowiak-Wojten K, Raczak A, Landowski J, Wiglusz MS, Gałuszko-Węgielnik M, Krysta K, Cubała WJ.

Psychiatr Danub. 2017 Sep;29(Suppl 3):353-356.

PMID:
28953790
17.

Benzodiazepines as adjunctive therapy in treatment refractory symptoms of schizophrenia.

Szarmach J, Włodarczyk A, Cubała WJ, Wiglusz MS.

Psychiatr Danub. 2017 Sep;29(Suppl 3):349-352.

PMID:
28953789
18.

Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.

Włodarczyk A, Szarmach J, Cubała WJ, Wiglusz MS.

Psychiatr Danub. 2017 Sep;29(Suppl 3):345-348.

PMID:
28953788
19.
20.

Magnesium, C-reactive protein, and cortisol in drug-naïve patients with short illness-duration, first episode major depressive disorder: possible immunomodulatory role for magnesium.

Cubała WJ, Landowski J, Dziadziuszko M, Chrzanowska A, Wielgomas B.

Magnes Res. 2016 Apr 1;29(4):169-174. doi: 10.1684/mrh.2016.0413.

PMID:
27965189

Supplemental Content

Loading ...
Support Center